Microdialysis could help you to analyze the efficacy of the drug delivery.
Moreover Magnetic resonance spectroscopy is non-invasive imaging that can be used to assess neurometabolite alterations before and after treatment.
Ref:
Pharmacokinetics of BPA in gliomas with ultrasound-induced blood-brain barrier disruption as measured by microdialysis, DOI: 10.1371/journal.pone.0100104
Application of NMR spectroscopy in medicinal chemistry and drug discovery
You can either use in vitro models, e.g., BBB endothelial cell monolayers for permeation studies, or perform in vivo brain uptake studies with subsequent separation of the vascular and tissue fraction of the brain before analyzing compound content
In general, a small lipophilic molecule that is not a substrate of P-gp will likely cross BBB.
I'd measure drug's level in the brain using HPLC,UPLC, or LC/mass/mass, depending on your lab's available toolbox. You'll get better results if you perfuse organs before collection using PBS to avoid mistaking the drug present in the cerebral vasculature for that which extravasated into the brain tissue.
AJ .Kastin and WA Banks have developed the methodology and used it for the last 30 years with many and many papers published.
Essentially you should label the compound, and: 1) administer it centrally using the intracerebroventricular route and then follow it peripherically; 2) ou administer it perifpherally generally the intraperitoneally route and then follow it centrally with the sacrifice of the animal and brain collection. Mice and rats can be used.